Myrbetriq vs Gemtesa
A side-by-side look at two urology medications advertised on TV. Informational only — not medical advice.
| US Myrbetriq | US Gemtesa | |
|---|---|---|
| Generic name | mirabegron | vibegron |
| Drug class | Beta-3 Adrenergic Agonist | Beta-3 Adrenergic Agonist |
| Treats | Overactive bladder | Overactive bladder |
| Category | Urology | Urology |
| Manufacturer | Astellas Pharma | Sumitomo (Urovant) |
| Year approved | 2012 | 2020 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $140M | $80M |
| Common side effects | Increased blood pressure, Urinary tract infection, Headache, Dry mouth | Headache, Urinary tract infection, Nasal congestion, Diarrhea |
Myrbetriq
Frequently asked questions
Is Myrbetriq or Gemtesa better?
Neither is universally "better." Myrbetriq (mirabegron) and Gemtesa (vibegron) are both used for urology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Myrbetriq and Gemtesa?
Myrbetriq is a Beta-3 Adrenergic Agonist made by Astellas Pharma, while Gemtesa is a Beta-3 Adrenergic Agonist made by Sumitomo (Urovant). See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Myrbetriq has the larger estimated TV advertising budget of the two.